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Abstract
Background: Detecting superficial head and neck squamous cell carcinoma (HNSCC) by endoscopy is challenging
because of limited morphological hallmarks, and iodine cannot be applied to head and neck lesions due to severe
mucosal irritation. γ-glutamyltranspeptidase (GGT), a cell surface enzyme, is overexpressed in several cancers, and it
has been reported that γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), a fluorescent targeting agent
which can be enzymatically activated and becomes fluorescent after cleavage of a GGT-specific sequence, can be
activated within a few minutes after application to animal models. We investigated whether early HNSCC can be
detected by applying gGlu-HMRG to clinical samples.
Methods: gGlu-HMRG was applied to four HNSCC cell lines, and fluorescence was observed by fluorescence
microscopy and flow cytometry. Immunohistological examination was performed in three recent cases of
endoscopic submucosal dissection (ESD) to investigate GGT expression. Fluorescence imaging with gGlu-HMRG in
eight clinical samples resected by ESD or surgery was performed, and fluorescence intensity of tumor and normal
mucosa regions of interest (ROI) was prospectively measured.
Results: All four gGlu-HMRG-applied cell lines emitted green fluorescence. Immunohistological examination
demonstrated that GGT was highly expressed in HNSCC of the recent three ESD cases but barely in the normal
mucosa. Fluorescence imaging showed that iodine-voiding lesions became fluorescent within a few minutes after
application of gGlu-HMRG in all eight resected tumors. Tumor ROI fluorescence intensity was significantly higher
than in the normal mucosa five minutes after gGlu-HMRG application.
Conclusions: Fluorescence imaging with gGlu-HMRG would be useful for early detection of HNSCC.
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Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world, with about
630,000 new cases diagnosed annually [1]. The prognosis
of HNSCC is poor because it is typically detected at the
advanced stage [2, 3]. However, patients with early-stage
HNSCC, such as stage I and II, achieve a better progno-
sis with a 70–90 % 5-year survival rate as compared with
patients with advanced HNSCC [4]. Therefore, early
detection of HNSCC is imperative, particularly for high-
risk patients, such as cigarette smokers and alcohol
abusers; however, early detection of superficial HNSCC
is very difficult because there are few morphological hall-
marks to differentiate the disease [5]. Although iodine chro-
moendoscopy has been widely accepted for detection of
early esophageal squamous cell carcinoma (SCC) [6, 7], it
cannot be applied to head and neck lesions in conventional
endoscopy because iodine causes severe mucosal irritation,
which can result in aspiration into the airways [8, 9].
Although narrow band imaging (NBI) and autofluores-
cence imaging (AFI) have been used to detect early
HNSCC, these modalities have not been widely accepted
[10, 11]. Therefore, an efficient and reliable method to
detect superficial HNSCC is required.
γ-glutamyltranspeptidase (GGT) is a cell surface en-
zyme involved in cellular glutathione metabolism and
has been reported to be overexpressed in several human
cancers, such as those of the lung, ovary, liver and bile
duct [12–14]. GGT has been reported to play a role in
tumor progression, invasion and drug resistance [12, 15].
It has been reported that γ-glutamyl hydroxymethyl
rhodamine green (gGlu-HMRG), a fluorescent targeting
agent that can be enzymatically activated, based on the
fluorophore rhodamine green, which becomes fluores-
cent after cleavage of a GGT-specific sequence, was
developed and gGlu-HMRG can be activated specifically
in seconds to minutes by topical application [16]. It has
also been demonstrated that gGlu-HMRG can improve
endoscopic detection of colitis-associated cancer with a
higher target-to-background ratio than conventional
white light colonoscopy in a murine model [17]. How-
ever, whether fluorescence imaging with gGlu-HMRG
can detect human HNSCC remains to be elucidated.
Accordingly, the aim of this study was to evaluate
whether superficial HNSCC can be detected by applica-
tion of gGlu-HMRG using fresh clinical samples ob-
tained by endoscopic submucosal dissection (ESD) or
local surgical resection.
Methods
Enzymatic-activatable fluorescent targeting agent
gGlu-HMRG was synthesized as previously described
[18], and resuspended in 10 mM dimethylsulfoxide
(DMSO, Sigma-Aldrich, St. Louis, Missouri) and stored
at −80 °C. When used, gGlu-HMRG was thawed at
room temperature and diluted to 1 or 100 μM using
phosphate-buffered saline (PBS, Life Technologies,
Carlsbad, California).
Cell culture
HNSCC cell lines—HSC2, HSC3 and HSC4—were ob-
tained from the American Type Culture Collection (ATCC;
Manassas, Virginia), and cultured in Dulbecco’s Modified
Eagle Medium (DMEM; Nacalai Tesque, Kyoto, Japan)
supplemented with 10 % fetal bovine serum (FBS; Life
Technologies), 100 U/mL of penicillin and 100 μg/mL of
streptomycin (Wako Pure Chemical Industries, Osaka,
Japan). SCC25 cells were obtained from the Japanese Col-
lection of Research Bioresources (JCRB, Osaka, Japan) and
cultured in DMEM/F-12 (Nacalai Tesque) supplemented
with 10 % FBS, 100 U/mL of penicillin and 100 μg/mL of
streptomycin. The culture was maintained at 37 °C in a
humidified atmosphere of 95 % air and 5 % CO2.
Fluorescence microscopy
Cells were cultured in 35-mm dishes; next, once the
cells had been reached at around 80 % confluence, cells
were washed with PBS, 1 μM of gGlu-HMRG was added
and cells were incubated in the dark for 20 min at 37 °C.
Fluorescence microscopy was performed using a Biorevo
BZ-9000 microscope (Keyence, Osaka, Japan), equipped
with the following filters: excitation wavelength, 450–
490 nm; emission wavelength, 500–550 nm. Phase con-
trast images were also developed.
Flow cytometry
Cultured cells were treated with 0.25 % trypsin/ethyl-
enediaminetetraacetic acid (Life Technologies), har-
vested and resuspended in PBS. Cells (1 × 106) were
incubated in the dark with 1 μM of gGlu-HMRG for
20 min at 37 °C and analysed using a flow cytometer
(FACSCanto II; Becton, Dickinson and Company,
Franklin Lakes, New Jersey).
Time course of fluorescence intensity in cultured cell lines
Cells (2 × 104) were cultured on a black 96-well plate
overnight and incubated with 1 μM of gGlu-HMRG with
or without 10 μM of GGT inhibitor (GGsTop®, Wako
Pure Chemical Industries). The time course of the fluor-
escence intensity was analysed using a microplate reader
(505–555 nm; Tecan, Mannedorf, Switzerland).
Patient studies
This study prospectively reviewed eight consecutive
HNSCC tumors treated by ESD and local surgical resection
in seven patients at the Department of Gastroenterology
and Hepatology and the Department of Otolaryngology-
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Head and Neck Surgery of Hokkaido University Hospital
between June 2014 and February 2016.
The indication of ESD or local surgical resection for
HNSCC are as follows; 1) within slight invasion in the sub-
epithelium and 2) no lymph node metastasis by computed
tomography. ESD was performed using a single-channel
gastrointestinal endoscope with a transparent attachment
hood fitted to the tip using a needle knife (KD-10Q-1,
Olympus, Tokyo, Japan) and insulation tip (IT knife, Olym-
pus) under general anesthesia [19]. All ESD procedures
were performed by an experienced endoscopist who had
performed over 100 esophageal ESD procedures.
Local surgical resection was performed using a
Colorado microdissection needle (Stryker, Kalamazoo,
Michigan) and an electrosurgical generator (Force FX,
Covidien, Dublin, Ireland) under general anesthesia.
The resected specimen was immediately extended on a
black rubber and fixed with pins. Next, 100 μM of gGlu-
HMRG was sprayed onto the specimen. Fluorescence
imaging was performed using a handheld fluorescent im-
aging system (Discovery; INDEC Medical Systems, Santa
Clara, California), which enables the capture of white-
light images and fluorescent images with 450–490 nm
blue excitation light. Fluorescence images were recorded
0, 0.5, 2, 5, 7, 9, 11 and 13 min after gGlu-HMRG admin-
istration. Subsequently, specimens were washed with PBS
and observed using an endoscope (H260Z, Olympus)
under a white light with 1.5 % iodine staining.
Fluorescence intensities were measured with Image J soft-
ware (National Institutes of Health, Rockville, Maryland).
Tumor and normal squamous mucosa regions of interest
(ROI) were manually traced on each image. The ROI of the
tumor was determined according to the iodine staining
images. The mean fluorescence intensity of each ROI was
calculated as pixel intensity values ranging from 0 to 255.
Histopathology
Specimens were fixed in 40 g/L of formaldehyde saline,
embedded in paraffin and cut into 5-μm sections. Tissue
sections were stained with hematoxylin and eosin (H&E)
and microscopically examined for histological type,
tumor size, depth of invasion, lymphovascular invasion
and resected margin by experienced pathologists, accord-
ing to the World Health Organization (WHO) classifica-
tion. Immunohistochemical analysis of GGT expression
was performed using an anti-GGT1 antibody (dilution,
1:600; Abcam, Cambridge, UK).
Statistical analysis
Data were expressed as means ± SEM. Parameters were
compared between the groups using a paired t-test. Dif-
ferences were considered significant at a P value < 0.05.
All analyses were performed using GraphPad Prism
version 6 (GraphPad Software, San Diego, California).
Results
Evaluation of gGlu-HMRG in HNSCC cell lines
To investigate GGT expression in HNSCC cells, gGlu-
HMRG fluorescence was examined using four cell lines
of HNSCC (HSC2, HSC3, HSC4 and SCC25). All tumor
cell lines emitted fluorescence following gGlu-HMRG
administration as evidenced by fluorescence microscopy
(Fig. 1a) and flow cytometry (Fig. 1b). Fluorescence in-
tensity was increased over time in all cell lines; however,
when cultured with a GGT inhibitor, fluorescence emis-
sion was completely blocked (Fig. 1c). These results sug-
gest that GGT is expressed in HNSCC cell lines and that
gGlu-HMRG is activated by GGT.
Expression of GGT in recent HNSCC cases treated with
ESD
To confirm tumor-specific expression of GGT in HNSCC,
we performed immunohistological examination of the
tumors of three recent cases that had been treated with
ESD. As shown in Fig. 2, GGT was expressed specifically
in the tumor and barely expressed in the basal layer of the
normal counterpart in all cases examined.
Ex vivo fluorescent imaging with gGlu-HMRG of HNSCC
cases treated with ESD or local surgical resection
We next evaluated whether early HNSCC can be detected
by spraying gGlu-HMRG using dissected specimens. ESD
and local surgical resection were performed in seven
patients with eight lesions. (Table 1). It was difficult to de-
tect the superficial tumors with white light (Fig. 3a), and
all cases were barely detected using narrow band imaging
(NBI, Fig. 3b). Iodine staining was performed both before
resection under general anesthesia (Fig. 3c) and after re-
section (Fig. 3d). Resected specimens were also sprayed
with gGlu-HMRG and fluorescence images were obtained
(Fig. 3e). In all cases, tumor lesions became fluorescent
within a few minutes corresponding to an area almost
exactly identical to the iodine-unstained lesion. In several
cases, the subsites of the resected mucosa became fluores-
cent even before applying gGlu-HMRG, and immunohis-
tological analysis did not show any positive staining for
GGT in the subsites of the resected mucosa. Therefore,
we speculate that autofluorescence was emitted by the
burning effect [20]. Histological analysis confirmed that
the iodine-unstained and fluorescent lesion were early
SCC expressing GGT in all cases (Fig. 3f–h).
Fluorescence intensity of tumor and normal epithelium
after spraying gGlu-HMRG
We finally measured the fluorescence intensity of both
tumor and normal epithelium of all eight cases for
13 min. The tumor lesion was traced according to the
iodine staining (Fig. 4a). The fluorescence intensity of
the tumor lesion increased immediately after gGlu-
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HMRG spraying and rose to a mean intensity of 7 at
13 min, while that of normal mucosa remained <2
(Fig. 4b). The matched rate between iodine-unstained
and gGlu-HMRG-induced fluorescent area was 74 %.
Discussion
In this study, we evaluated the use of gGlu-HMRG for the
detection of early HNSCC and found that (1) all HNSCC
cell lines examined emitted fluorescence following gGlu-
Fig. 1 Fluorescent imaging of HNSCC cell lines in vitro. a gGlu-HMRG fluorescence was detected by fluorescence microscopy. Phase contrast
images (left column), gGlu-HMRG fluorescence images (right column), Scale bars, 100 μm. b Flow cytometric analysis of GGT expression. Open
area; no gGlu-HMRG, Closed area; with gGlu-HMRG. c GGT inhibition in cell lines shows decreasing GGT activity over time, resulting in low
fluorescence intensity
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HMRG exposure; (2) HNSCC, but not normal tissue,
expressed GGT in three recent ESD cases; and (3) tumor
lesions became fluorescent immediately after gGlu-HMRG
being applied to all eight HNSCC cases.
It is difficult to detect superficial HNSCC using con-
ventional endoscopy with white light because mucosal
changes are usually very subtle [5, 21]. Recently, NBI
and AFI have been used to detect early cancers of the
upper gastrointestinal tract and have been reported to
be superior to white-light endoscopy in terms of sensi-
tivity, specificity and accuracy for the diagnosis of
HNSCC and esophageal SCC [10, 11, 21–26]. However,
these modalities were reported from a limited number of
institutes and hospitals and require remarkable expert
skills to be successfully employed. In addition, it has been
reported that the detection rate of early esophageal SCC
using NBI was 10–13 % for SCC high-risk groups [24, 25],
suggesting that it requires a sharp learning curve for the
detection of HNSCC with NBI [27]. Furthermore, inflam-
matory changes in the larynx have been reported to cause
false positive results in AFI [23]. Therefore, the develop-
ment of a novel method with which even a non-expert
gastroenterologist or otolaryngologist can detect early
HNSCC is warranted.
When the gGlu-HMRG as targeting agent encounters
GGT on the surface of cancer cells, it is hydrolysed by
GGT, becoming highly fluorescent HMRG. HMRG is
immediately taken up by cancer cell lysosomes through
the cell membrane [16]. Therefore, HMRG is expected
to emit strong fluorescence in cancer lesions. Accord-
ingly, it has been demonstrated that topical spraying of
gGlu-HMRG could provide immediate and specific
enhancement of cells overexpressing GGT in animal
models [16, 17]. In addition, it has been recently demon-
strated, in a pilot study of fluorescence imaging of endo-
scopically resected colorectal tumors, that topical spraying
of gGlu-HMRG enabled rapid and selective fluorescence
imaging of 54 % and 76 % of adenomas and carcin-
omas in adenoma, respectively [28]. Although the au-
thors used 50 or 500 μM of gGlu-HMRG, our results
Fig. 2 Immunohistological anaylsis of GGT expression in the past three HNSCC cases treated with ESD. Resected specimens were stained with
hematoxylin and eosin (left) and an anti-GGT1 antibody (right). Scale bars, 500 μm. Dotted and solid lines indicate the part of normal eithelium
and tumor, respectively
Table 1 Patient characteristics
Patient No. Site of lesion Size (mm) Treatment Morphology Depth
1 Hypopharynx 5 × 4 ESD IIb Tis
2 Hypopharynx 10 × 7 ESD IIa + IIb Tis
3 Hypopharynx 32 × 19 ESD IIb + Is T2
4 Epiglottis 12 × 9 ESD IIb T1
5 Soft palate 20 × 15 Surgery IIb T1
6 Hypopharynx 17 × 13 ESD IIb T1
6 Hypopharynx 7 × 6 ESD IIb T1
7 Hypopharynx 16 × 15 ESD IIb + IIa T1
ESD endoscopic submucosal dissection. Age ranges from 65 to 79
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Fig. 3 Ex vivo fluorescent imaging with gGlu-HMRG of two representative HNSCC cases (cases #1 and #5). a Endoscopic imaging with white light.
b Narrow band imaging (NBI). c Iodine staining performed under general anesthesia. d Resected specimen observed with iodine staining.
e Fluorescent imaging after spraying gGlu-HMRG. f Resected specimen mapping for tumor region. SCC was shown in red line. g
Hematoxylin and eosin staining of the tumor and normal component. h Immunohistochemical examination investigating GGT expression
in the tumor and normal component. Square lines in f correspond to the upper figures in g and h. Dotted square lines in f correspond
to the lower figures in g and h. Scale bars of d-f, 1 mm (case#1) and 5 mm (case#5). Scale bars of g and h, 200 μm
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suggested that using 100 μM of gGlu-HMRG is suffi-
cient for tumor detection.
Immunohistological examination demonstrated that
GGT was highly expressed in tumor tissue but barely
expressed at the basal lamina of the normal epithelium.
The fluorescence intensity of the normal epithelium was
very weak; however, it gradually became stronger with
time. This is probably because it took a longer time for
gGlu-HMRG to reach the basal lamina, which only
weakly expresses GGT, than to reach the tumor cells.
There are several limitations to this study. Because
the study was performed ex vivo, GGT activity may
have decreased to some extent following tumor resec-
tion. It took 10–20 min to initiate fluorescence imaging
after tumor resection, and imaging was performed at
room temperature rather than at 37 °C. Therefore, it
is expected that gGlu-HMRG would react faster in an
in vivo clinical study than in an ex vivo study. In
addition, because this is a pilot study investigating
only eight cases, it remains to be elucidated whether
all superficial HNSCC and precancer lesion can be
detected with gGlu-HMRG. Future clinical trials
studying a larger number of HNSCC cases would
clarify these concerns.
Conclusions
In conclusion, topical spraying of gGlu-HMRG enabled
rapid and specific fluorescence imaging of superficial
HNSCC, and appears to be useful in the early detection
of HNSCC.
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